196
Views
58
CrossRef citations to date
0
Altmetric
Research Article

Magnetic PECA nanoparticles as drug carriers for targeted delivery: Synthesis and release characteristics

, , , &
Pages 203-212 | Received 30 May 2005, Accepted 10 Jul 2005, Published online: 08 Oct 2008
 

Abstract

Magnetic poly(ethyl-2-cyanoacrylate) (PECA) nanoparticles containing anti-cancer drugs (Cisplatin and Gemcitabine) were prepared by inter-facial polymerization. The spherical nanoparticles (d = 250 ± 15 nm) with smooth surfaces and moderately uniform size distributions were obtained. The amount of magnetite encapsulated inside the polymer matrix was increased up to 14.26% (w/w) by controlling the initial weight ratio of monomer/magnetite. It was found that the amount of Cisplatin encapsulated in the magnetic nanoparticle is much higher than that of Gemcitabine because Cisplatin (hydrophobic) is highly soluble in the oil phase and encapsulated easier inside nanoparticles compared to Gemcitabine (hydrophilic). The presence of magnetite and its super-paramagnetic characteristic were confirmed by FTIR spectra and VSM. In-vitro experiments of drug release and magnetic mobility under external magnetic field demonstrated that magnetic poly(ethyl-2-cyanoacrylate) (PECA) nanoparticles can be a highly versatile magnetic drug carrier with sustained release behaviour and sufficient magnetic susceptibility.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.